NasdaqGM:SMMTBiotechs
Assessing Summit Therapeutics (SMMT) Valuation After Ivonescimab FDA Filing And New GSK Trial Collaboration
Summit Therapeutics (SMMT) has drawn fresh attention after submitting a Biologics License Application for its lead drug ivonescimab in advanced lung cancer and pairing it with a new combination trial collaboration with GSK.
See our latest analysis for Summit Therapeutics.
Despite the fresh clinical news and collaboration headlines, Summit Therapeutics' 7 day share price return of 9.91% and 90 day share price return of 25.75% are negative. However, its 3 year total shareholder return of about...